clinical Programs

ANG-3777: A SMALL MOLECULE
HARNESSING HGF

ANG-3777 MIMICS, SUPPLEMENTS, AND ENHANCES THE EFFECTS OF HGF

ANG-3777 mimics hepatocyte growth factor (HGF) to prevent cell death, activate self-repair and stimulate regeneration following organ injury. ANG-3777 extends the body’s window for therapeutic intervention in the setting of organ injury. Unlike other therapies, it is effective even when dosed 24 hours or beyond organ damage.

 
Graph+1.jpg

ANG-3777’s effectiveness when dosed after injury is a critical differentiating factor both in terms of clinical trial design and therapeutic window for treatment.

When injury occurs in AKI, HGF is immediately released from storage (blue line) and the body’s reserves are significantly depleted.
An upregulation of c-Met starts at time of injury (red line).
At 24 hours (light blue bar), there is maximal expression of c-Met receptors presenting an opportunity to enhance the critical activity of this anti-cell death and regenerative pathway.
ANG-3777, a small organic molecule, is an HGF mimetic.
Dosing with ANG-3777 at 24, 48, and 72 hours supplements the depleted HGF, binding with the underutilized but upregulated c-Met receptors.
By enhancing the kidney’s ability to self-repair, ANG-3777 prevents and reduces further renal injury.

 
AdobeStock_101201109.jpeg

ANG-3777 & DELAYED GRAFT FUNCTION ASSOCIATED ACUTE KIDNEY INJURY

A phase 2 trial investigating ANG-3777 in delayed graft function associated acute kidney injury (DGF-AKI) demonstrated improved clinical outcomes in patients when given within 36 hours of renal transplant. Treatment demonstrated improved urine production and kidney function. The ANG-3777 treated group had a 36% reduction in duration of DGF.

A phase 3 trial of ANG-3777 in DGF is currently enrolling.

 
Acute Kidney Injury.png
 

ANG-3777 & CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY

More than 350,000 cardiac surgeries are performed annually in the U.S. Cardiac surgery associated AKI (CSA-AKI) is the most common significant complication that develops after cardiac surgery. Developing this condition leads to a doubling of morbidity and mortality in affected patients and severe cases of CSA-AKI may generate mortality rates of up to 50%. The current standard of care is increased hospitalization and dialysis.

A phase 2 trial investigating ANG-3777 for the treatment of CSA-AKI is currently enrolling.

Additional potential indications for ANG-3777 include stroke, corneal scarring, heart injury, acute lung injury, and acute liver injury.